Kah Poh Loh1, Maya Abdallah2, Anita J Kumar3,4, Nina R Neuendorff5, Saurabh Dahiya6, Heidi D Klepin7. 1. James P. Wilmot Cancer Institute, Division of Hematology/Oncology, University of Rochester Medical Center, 601 Elmwood Avenue, Box 704, Rochester, NY, 14642, USA. kahpoh_loh@urmc.rochester.edu. 2. Department of Internal Medicine, University of Massachusetts Medical School-Baystate, Springfield, MA, USA. 3. Division of Hematology/Oncology, Tufts Medical Center, Boston, MA, USA. 4. Institute for Clinical Research & Health Policy Studies, Tufts Medical Center, Boston, MA, USA. 5. Department of Internal Medicine V, Hematology, Oncology and Rheumatology, University Hospital Heidelberg, Heidelberg, Germany. 6. Marlene and Stewart Greenebaum Cancer Center, University of Maryland School of Medicine, Baltimore, MD, USA. 7. Section on Hematology and Oncology, Wake Forest Baptist Comprehensive Cancer Center, Medical Center Blvd, Winston-Salem, NC, USA.
Abstract
PURPOSE OF REVIEW: The treatment landscape for older patients with acute myeloid leukemia (AML) is evolving. Many treatments have comparable efficacy making their impact on quality of life (QoL) an important differentiating factor. In this review, we discuss QoL in older adults with AML, focusing on therapeutic and observational trials that have incorporated QoL assessments. RECENT FINDINGS: Health-related quality of life (HRQoL) is a multi-dimensional concept incorporating physical, mental, emotional, and social functioning domains. HRQoL components overlap with components of geriatric assessment, a multidisciplinary diagnostic process that identifies underlying vulnerabilities of older adults and guides subsequent management strategies. HRQoL questionnaires may be general, cancer-specific, leukemia-specific, or symptom-focused. Therapeutic and observational cohort studies suggest HRQoL improves, or at least remains stable, during intensive and lower-intensity therapies. Nonetheless, HRQoL is not routinely incorporated in AML therapeutic trials. HRQoL assessments can inform both decision-making and management for older adults with AML.
PURPOSE OF REVIEW: The treatment landscape for older patients with acute myeloid leukemia (AML) is evolving. Many treatments have comparable efficacy making their impact on quality of life (QoL) an important differentiating factor. In this review, we discuss QoL in older adults with AML, focusing on therapeutic and observational trials that have incorporated QoL assessments. RECENT FINDINGS: Health-related quality of life (HRQoL) is a multi-dimensional concept incorporating physical, mental, emotional, and social functioning domains. HRQoL components overlap with components of geriatric assessment, a multidisciplinary diagnostic process that identifies underlying vulnerabilities of older adults and guides subsequent management strategies. HRQoL questionnaires may be general, cancer-specific, leukemia-specific, or symptom-focused. Therapeutic and observational cohort studies suggest HRQoL improves, or at least remains stable, during intensive and lower-intensity therapies. Nonetheless, HRQoL is not routinely incorporated in AML therapeutic trials. HRQoL assessments can inform both decision-making and management for older adults with AML.
Authors: Samuel D Slavin; Alyssa Fenech; Amanda L Jankowski; Gregory A Abel; Andrew M Brunner; David P Steensma; Amir T Fathi; Daniel J DeAngelo; Martha Wadleigh; Gabriela S Hobbs; Philip C Amrein; Richard M Stone; Jennifer S Temel; Areej El-Jawahri Journal: Cancer Date: 2019-07-12 Impact factor: 6.860
Authors: Hervé Dombret; John F Seymour; Aleksandra Butrym; Agnieszka Wierzbowska; Dominik Selleslag; Jun Ho Jang; Rajat Kumar; James Cavenagh; Andre C Schuh; Anna Candoni; Christian Récher; Irwindeep Sandhu; Teresa Bernal del Castillo; Haifa Kathrin Al-Ali; Giovanni Martinelli; Jose Falantes; Richard Noppeney; Richard M Stone; Mark D Minden; Heidi McIntyre; Steve Songer; Lela M Lucy; C L Beach; Hartmut Döhner Journal: Blood Date: 2015-05-18 Impact factor: 22.113
Authors: M A Sekeres; R M Stone; D Zahrieh; D Neuberg; V Morrison; D J De Angelo; I Galinsky; S J Lee Journal: Leukemia Date: 2004-04 Impact factor: 11.528
Authors: Ashley M Nelson; Hermioni L Amonoo; Alison R Kavanaugh; Jason A Webb; Vicki A Jackson; Julia Rice; Mitchell W Lavoie; Amir T Fathi; Andrew M Brunner; Joseph A Greer; Jennifer S Temel; Areej El-Jawahri; Thomas W LeBlanc Journal: Cancer Date: 2021-08-30 Impact factor: 6.921
Authors: Ursula Rochau; Igor Stojkov; Annette Conrads-Frank; Helena H Borba; Karin A Koinig; Marjan Arvandi; Corine van Marrewijk; Hege Garelius; Ulrich Germing; Argiris Symeonidis; Guillermo F Sanz; Pierre Fenaux; Theo de Witte; Fabio Efficace; Uwe Siebert; Reinhard Stauder Journal: Br J Haematol Date: 2020-05-14 Impact factor: 6.998